Ntawm no yog vim li cas Turning Point Therapeutics dhia 110%

Hloov Point Therapeutics Inc (NASDAQ: TPTX) dhia 110% tom qab tshaj tawm qhov kev pom zoo sib koom ua ke nrog Bristol Myers Squibb Co., Ltd.NYSE: BMY). Raws li kev pom zoo, Bristol Myers Squibb yuav tau txais Turning Point ntawm $ 76 ib feem. Pawg Thawj Coj Thawj Coj ntawm ob qho tib si Turning Point thiab Bristol Myers Squibb tau lees paub qhov kev pom zoo, uas xav tias yuav kaw hauv Q3 2022.

Bristol Myers los nthuav nws cov kev lag luam oncology nrog kev nrhiav tau ntawm Turning Point

Bristol Myers CEO Giovanni Caforio tau hais tias:

Puas yog koj tab tom nrhiav kom tau cov xov xwm ceev, kub-cov lus qhia thiab kev tsom xam kev ua lag luam?

Sau npe rau Invezz cov ntawv xov xwm, hnub no.

Kev nrhiav tau ntawm Turning Point Therapeutics txuas ntxiv nthuav dav peb cov thawj coj ntawm oncology franchise los ntawm kev ntxiv qhov zoo tshaj plaws-hauv-chav kawm, late-stage precision oncology cuab tam. Tsis tas li ntawd, peb tab tom txuas ntxiv peb cov ntaub ntawv muaj zog ntawm kev txhim kho kev lag luam nrog cov kev lag luam no txhawm rau txhim kho peb txoj kev loj hlob ntxiv.

Turning Point yog lub tuam txhab oncology precision tsim cov ntaub ntawv ntawm kev sim tshuaj uas tsom mus rau lub hom phiaj ntawm kev hloov pauv uas feem ntau txuas rau oncogenesis. Repotrectinib, lub tuam txhab lub cuab tam tseem ceeb, yog ib tug tom ntej-gen tyrosine kinase inhibitor (TKI) uas lub hom phiaj ntawm ROS1 thiab NTRK oncogenic txoj kev ntawm non-me me cell ntsws cancer (NSCLC) nrog rau lwm yam kab mob lig.

US FDA tau muab tsub rau Repotrectinib peb Txoj Kev Kho Mob Kho Mob. Hauv qhov kev ntsuam xyuas meej ntawm Phase 1/2 TRIDENT-1 kev tshawb fawb soj ntsuam, repotrectinib tau pom tias muaj lub sijhawm ua haujlwm ntev dua li cov tshuaj ROS1 tam sim no hauv thawj kab NSCLC.

Bristol Myers Tus Thawj Saib Xyuas Kev Kho Mob Ntiaj Teb Kev Txhim Kho Tshuaj Samit Hirawat tau hais tias:

Cov xov xwm niaj hnub no tsim los ntawm peb cov keeb kwm ntev ntawm kev pioneer tshuaj tshiab rau cov neeg mob qog noj ntshav. Nrog repotrectinib, peb muaj lub sijhawm los hloov tus qauv kev saib xyuas thiab hais txog qhov kev xav tau kev kho mob tseem ceeb rau ROS1-zoo uas tsis yog me me ntawm cov neeg mob qog noj ntshav.

Kev sib koom ua ke los pab Turning Point Therapeutics tsim cov tshuaj oncology 

Los ntawm kev sib pauv, Turning Point yuav muaj peev xwm paub txog tag nrho cov peev txheej ntawm nws qhov tseeb oncology platform los tsim cov qauv kev kho mob rau cov neeg mob qog noj ntshav. Txij li thaum nws tsim, Turning Point tau siv kev paub txog kev tshawb fawb tob tob kom ua tiav cov kav dej ntawm cov tshuaj oncology precision.

Turning Point CEO thiab Thawj Tswj Hwm Athena Countouriotis xaus lus:

Nrog Bristol Myers Squibb txoj kev coj noj coj ua hauv oncology, muaj peev xwm ua lag luam muaj zog, thiab tsim cov hneev taw, peb yuav muaj peev xwm ua kom nrawm dua qhov uas peb tuaj yeem nqa peb cov tshuaj tshiab los pab cov neeg mob qog noj ntshav thoob ntiaj teb.